Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Gene silencing and gene editing
CRISPR patent decisions could trigger waves globally
By
LabPulse.com staff writers
Canceling a pair of patents in Europe will affect a broad network of biotech companies that have bought and sold the rights to pursue gene-slicing research, according to a September 25 report published in
MIT Technology Review
.
September 30, 2024
Vertex sues HHS for Casgevy fertility program access
By
LabPulse.com staff writers
Vertex Pharmaceuticals filed a lawsuit against the U.S. Department of Health and Human Services seeking to be permitted to offer its fertility support services program to Medicaid patients who have been prescribed its Casgevy gene-editing treatment.
July 16, 2024
Researchers discover new class of guide RNA for genome editing
By
Liz Carey
Bridge RNA recombination may lead to precise gene insertions at specific sites across the genome beyond single-gene disruption and open new pathways for understanding how genes influence health and disease.
July 10, 2024
Roche, Ascidian to develop gene therapies for neurological diseases
By
LabPulse.com staff writers
Roche has announced a research collaboration and licensing agreement with biotech firm Ascidian Therapeutics to develop gene therapies for neurological diseases.
June 19, 2024
New approach may improve CRISPR safety, accuracy
By
LabPulse.com staff writers
Modulating a DNA repair pathway may improve the safety and accuracy of the use of CRISPR technology, according to a team of researchers.
May 21, 2024
Engineered Cas clears barrier to antiviral CRISPR therapies
By
Nick Paul Taylor
Researchers have engineered a Cas enzyme to enhance activity against RNA viruses, resulting in a system that completely blocked the replication of various SARS-CoV-2 strains.
April 19, 2024
Gene-based technique shows potential for rapid diagnostics
By
LabPulse.com staff writers
Biomedical engineers have developed a new gene-based approach which can be used on test strips for rapid, on-the-spot disease detection with accuracy comparable to that of lab-based polymerase chain reaction (PCR) tests.
March 7, 2024
Reversible, multiplex CRISPR system enhances efficacy of CAR-T cell therapy
By
Nick Paul Taylor
A CRISPR system that uses Cas13d to make reversible changes to the expression of multiple genes could overcome limitations that are holding back CAR-T cell therapies, a paper published in Cell suggests.
February 28, 2024
Intellia Therapeutics, ReCode Therapeutics to collaborate on genomic medicines for CF
By
LabPulse.com staff writers
Gene-editing firm Intellia Therapeutics and biotech company ReCode Therapeutics have entered into a strategic collaboration aimed at developing genomic medicines for the treatment of cystic fibrosis (CF).
February 16, 2024
CRISPR and nanopore technology enable sensitive and specific mpox detection
By
Nick Paul Taylor
A test that combines CRISPR gene editing and nanopore sensing technology could accelerate the detection of mpox and other pathogens, according to a paper published in
Biosensors and Bioelectronics
.
February 16, 2024
Sensorion receives clinical trial approval for congenital deafness gene therapy
By
LabPulse.com staff writers
French biotech firm Sensorion has received approval to initiate a phase I and II clinical trial in France of SENS-501 (the OTOF-GT program), its gene therapy for gene-mediated hearing impairment.
January 22, 2024
First FDA-approved CRISPR-based gene therapy cleared for 2nd indication
By
LabPulse.com staff writers
A month after the U.S. Food and Drug Administration (FDA) approved Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, the agency has given it a second U.S. regulatory approval ahead of schedule.
January 17, 2024
Page 1 of 7
Next Page